木犀草素对白血病K562/ADR细胞多药耐药的逆转作用及机制研究

doi:10.11958/20230722

天津医药 ›› 2023, Vol. 51 ›› Issue (12): 1321-1325.doi: 10.11958/20230722

木犀草素对白血病K562/ADR细胞多药耐药的逆转作用及机制研究

周欣宇¹(), 李京敏², 张婷¹, 贾秀红¹^,^△()

1.滨州医学院附属医院儿科（邮编256603）
2.滨州医学院基础医学院人体解剖学教研室

收稿日期:2023-05-18 修回日期:2023-07-20 出版日期:2023-12-15 发布日期:2023-12-22
通讯作者: ^△ E-mail：jiaxiuhong001@163.com
作者简介:周欣宇（1995），女，硕士在读，主要从事白血病的发病机制及治疗方面研究。E-mail：zhouxinyu002x@163.com
基金资助:
山东省自然科学基金资助项目(ZR2014HL032);山东省医药卫生科技发展计划项目(2017WS038)

Study on the mechanism of luteolin reversing multidrug resistance in leukemia K562/ADR cells

ZHOU Xinyu¹(), LI Jingmin², ZHANG Ting¹, JIA Xiuhong¹^,^△()

1. Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256603, China
2. Department of Human Anatomy, Basic Medical College, Binzhou Medical University

Received:2023-05-18 Revised:2023-07-20 Published:2023-12-15 Online:2023-12-22
Contact: ^△ E-mail：jiaxiuhong001@163.com

周欣宇, 李京敏, 张婷, 贾秀红. 木犀草素对白血病K562/ADR细胞多药耐药的逆转作用及机制研究[J]. 天津医药, 2023, 51(12): 1321-1325.

ZHOU Xinyu, LI Jingmin, ZHANG Ting, JIA Xiuhong. Study on the mechanism of luteolin reversing multidrug resistance in leukemia K562/ADR cells[J]. Tianjin Medical Journal, 2023, 51(12): 1321-1325.

摘要/Abstract

摘要：

目的探究木犀草素（Lut）对慢性髓系白血病K562/ADR细胞多药耐药性的逆转作用及其机制。方法 K562和K562/ADR细胞经不同浓度阿霉素（ADR）处理24 h后，采用CCK-8实验检测K562/ADR细胞耐药倍数。Lut单独或联合ADR作用K562/ADR细胞24 h后，采用CCK-8实验检测Lut的细胞毒性及对ADR的增敏作用。取对数生长期K562/ADR细胞分为0 μmol/L Lut组、2 μmol/L Lut组、4 μmol/L Lut组，采用流式细胞术检测细胞内ADR蓄积量的变化；RT-PCR法和Western blot法分别检测核因子E2相关因子2（Nrf2）、多药耐药相关蛋白1（MRP1）、P-糖蛋白（P-gp）、谷胱甘肽-S-转移酶pi（GST-pi）mRNA和蛋白的表达；谷胱甘肽（GSH）试剂盒检测细胞内GSH的含量。结果与K562细胞相比，K562/ADR细胞株对ADR具有明显的耐药性，耐药倍数为53.69倍。与0 μmol/L Lut相比，不同浓度Lut作用于K562/ADR细胞后，细胞生长均受到不同程度的抑制（P<0.05），其中2、4 μmol/L Lut对K562/ADR细胞的增殖抑制率<10%，为无毒性的Lut浓度。与0 μmol/L Lut组相比，2、4 μmol/L Lut组可明显增强ADR对K562/ADR的细胞增殖抑制率，增加细胞内ADR蓄积量，提高逆转耐药倍数，降低细胞内GSH含量，下调细胞中MRP1、P-gp、GST-pi、Nrf2 mRNA及蛋白的表达（P<0.05）；且4 μmol/L Lut作用效果较2 μmol/L Lut更显著。结论 Lut可抑制K562/ADR细胞增殖，逆转其对ADR的耐药性，其机制可能与Lut下调Nrf2、MRP1、P-gp、GST-pi表达，进而增加细胞内ADR蓄积量有关。

关键词: 白血病, 髓系, 慢性, BCR-ABL阳性, 木犀草素, 抗药性, 多药, 核因子E2相关因子2, 多药耐药相关蛋白1, P-糖蛋白, 谷胱甘肽-S-转移酶pi

Abstract:

Objective To investigate the mechanism of luteolin′s (Lut) reversal effect on multidrug resistance of chronic myeloid leukemia K562/ADR cells. Methods CCK-8 assay was used to detect drug resistance in K562 and K562/ADR cells 24 hours after treatment with different doses of adriamycin (ADR). CCK-8 assay was used to assess the cytotoxicity and sensitizing effect of Lut on ADR after K562/ADR cells were treated with Lut alone or in combination with ADR for 24 hours. K562/ADR cells in logarithmic growth phase were separated into three group: 0 μmol/L Lut, 2 μmol/L and 4 μmol/L Lut groups. ADR accumulation in cells was measured using flow cytometry. Nuclear factor erythroid-2-related factor 2 (Nrf2), multidrug resistance associated protein 1 (MRP1), P-glycoprotein (P-gp) and glutathione-S-transferase-PI (GST-pi) mRNA and protein expressions were identified using RT-PCR and Western blot assay. Glutathione (GSH) kit was used to detect intracellular GSH content. Results Compared with K562 cells, K562/ADR cell line was significantly resistant to ADR, and the drug resistance was 53.69 times. K562/ADR cell proliferation was decreased to variable degrees by different doses of Lut when compared to the 0 μmol/L Lut group (P<0.05). The proliferation inhibition rates of K562/ADR cells treated with 2 and 4 μmol/L Lut were less than 10%, indicating that the concentration of Lut was non-toxic. Compared with the 0 μmol/L Lut group, the 2 μmol/L Lut group and the 4 μmol/L Lut group showed significantly increased ADR growth inhibition rate on K562/ADR and increased accumulation of ADR in cells, improved the reversal resistance fold, and decreased GSH content in cells. MRP1, P-gp, GST-pi and Nrf2 mRNA and protein expression were reduced in cells (P<0.05). The effect of 4 mol/L Lut was greater than that of 2 mol/L Lut. Conclusion Lut may decrease K562/ADR cell proliferation and reverse ADR medication resistance. The mechanism could be connected to the downregulation of Nrf2, MRP1, P-gp and GST-pi expression, which leads to an increase in ADR accumulation in K562/ADR cells.

Key words: leukemia, myelogenous, chronic, BCR-ABL positive, Luteolin, drug resistance, multiple, nuclear factor erythroid2-related factor 2, multidrug resistance associated protein 1, P-glycoprotein, glutathione-S-transferase-PI

中图分类号:

R733.72

图/表 5

表1 RT-PCR引物序列

Tab.1 Primer sequence of RT-PCR

基因名称	引物序列（5'→3'）	产物大小/bp
MRP1	上游：CCTGGGCATTTCACAAGGGAT	139
MRP1	下游：GGTCCGCTCAAAGAAGCTCA	139
P-gp	上游：CCACAGAGGGGATGGTCAGT	142
P-gp	下游：GGTCCGCTCAAAGAAGCTCA	142
GST-pi	上游：AGCCTTTTGAGACCCTGCTGC	122
GST-pi	下游：AGGGGCTAGGACCTCATGGAT	122
Nrf2	上游：TAGTGCCCCTGGAAGTGTCAA	112
Nrf2	下游：ATCATGCACGTGAGTGCTCTG	112
GAPDH	上游：GCACCGTCAAGGCTGAGAAC	138
GAPDH	下游：TGGTGAAGACGCCAGTGGA	138

图1 不同浓度Lut对K562/ADR细胞ADR敏感性的影响 n=3，ADR质量浓度为16、32、64、128 mg/L的F值分别为9.425、14.110、37.480和14.140，均P<0.05；a与0 μmol/L+ADR组比较，b与2 μmol/L+ADR组比较，P<0.05。

Fig.1 Effect of different concentrations of Lut on the sensitivity of K562/ADR cells to ADR

表2 各组MRRP1、P-gp、Nrf2、GST-pi mRNA相对表达水平比较

Tab.2 Comparison of relative expression levels of MRRP1, P-gp, Nrf2 and GST-pi mRNA between the three groups （n=3，$\bar{x}±s$）

组别	MRP1	P-gp	Nrf2	GST-pi
0 μmol/L Lut组	1	1	1	1
2 μmol/L Lut组	0.76±0.05^a	0.53±0.07^a	0.57±0.14^a	0.88±0.04^a
4 μmol/L Lut组	0.67±0.02^ab	0.36±0.05^ab	0.35±0.20^a	0.64±0.08^ab
F	101.700^＊	130.300^＊	15.650^＊	48.690^＊

图2 Western blot检测各组细胞MRP1、P-gp、Nrf2、GST-pi蛋白表达 A、B、C分别为1、2、4 μmol/L Lut组。

Fig.2 The expressions of MRP1, P-gp, Nrf2 and GST-pi detected by Western blot assay

表3 各组细胞MRP1、P-gp、Nrf2、GST-pi蛋白相对表达水平比较

Tab.3 Comparison of relative expression levels of MRP1, P-gp, Nrf2 and GST-pi proteins between the three groups （n=3，$\bar{x}±s$）

组别	MRP1	P-gp	Nrf2	GST-pi
0 μmol/L Lut组	1.15±0.10	1.42±0.03	1.89±0.19^a	1.20±0.11
2 μmol/L Lut组	0.78±0.13^a	1.04±0.03^a	1.18±0.17^a	0.78±0.05^a
4 μmol/L Lut组	0.51±0.06^ab	0.69±0.06^ab	0.85±0.17^a	0.47±0.07^ab
F	31.370^＊	237.800^＊	27.090^＊	63.940^＊

参考文献 18

[1]	MINCIACCHI V R, KUMAR R, KRAUSE D S. Chronic myeloid leukemia:a model disease of the past,present and future[J]. Cells, 2021, 10(1):117. doi:10.3390/cells10010117.
[2]	YANG K, FU L W. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies:a review[J]. Crit Rev Oncol Hematol, 2015, 93(3):277-292. doi:10.1016/j.critrevonc.2014.11.001.
[3]	RUMJANEK V M, VIDAL R S, MAIA R C. Multidrug resistance in chronic myeloid leukaemia:how much can we learn from MDR-CML cell lines?[J]. Biosci Rep, 2013, 33(6):e00081. doi:10.1042/BSR20130067.
[4]	EL-SHIEKH R A, ELHEMELY M A, NAGUIB I A, et al. Luteolin 4'-neohesperidoside inhibits clinically isolated resistant bacteria in vitro and in vivo[J]. Molecules, 2023, 28(6):2609. doi:10.3390/molecules28062609.
[5]	QIN T, ZHU W J, KAN X L, et al. Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384[J]. J Bone Oncol, 2022, 34:100429. doi:10.1016/j.jbo.2022.100429.
[6]	彭艳辉, 段智, 李涛. 木犀草素对K562细胞增殖与凋亡的影响及其机制[J]. 天津医药, 2021, 49(3):236-241.
	PENG Y H, DUAN Z, LI T, Effects and mechanism of luteolin on the proliferation and apoptosis of K562 cells[J]. Tianjin Med J, 2021, 49(3):236-241. doi:10.11958/20202294.
[7]	许一诺, 唐姣, 任诗帆, 等. 木犀草素逆转宫颈癌细胞对阿霉素耐药性的机制研究[J]. 肿瘤药学, 2022, 12(2):183-190.
	XU Y N, TANF J, REN S F, et al. Luteolin reverses doxorubicin resistance in cervical cancer by regulating PI3K/Akt signaling pathway[J]. Anti-Tumor Pharmacy J, 2022, 12(2):183-190. doi:10.3969/j.issn.2095-1264.2022.02.07.
[8]	ASSARAF Y G, BROZOVIC A, GONÇALVES A C, et al. The multi-factorial nature of clinical multidrug resistance in cancer[J]. Drug Resist Updat, 2019, 46:100645. doi:10.1016/j.drup.2019.100645.
[9]	FLETCHER J I, WILLIAMS R T, HENDERSON M J, et al. ABC transporters as mediators of drug resistance and contributors to cancer cell biology[J]. Drug Resist Updat, 2016, 26:1-9. doi:10.1016/j.drup.2016.03.001.
[10]	WEEN M P, ARMSTRONG M A, OEHLER M K, et al. The role of ABC transporters in ovarian cancer progression and chemoresistance[J]. Crit Rev Oncol Hematol, 2015, 96(2):220-256. doi:10.1016/j.critrevonc.2015.05.012.
[11]	HANSSEN K M, HABER M, FLETCHER J I. Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers:beyond pharmacological inhibition[J]. Drug Resist Updat, 2021, 59:100795. doi:10.1016/j.drup.2021.100795.
[12]	JI L L, LI H, GAO P, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer[J]. PLoS One, 2013, 8(5):e63404. doi:10.1371/journal.pone.0063404.
[13]	GAO H L, XIA Y Z, ZHANG Y L, et al. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines[J]. Phytomedicine, 2019, 58:152885. doi:10.1016/j.phymed.2019.152885.
[14]	XIE Y, FENG S L, HE F, et al. Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer[J]. Pharmacol Res, 2022, 186:106514. doi:10.1016/j.phrs.2022.106514.
[15]	CUI J, LI G Q, YIN J, et al. GSTP1 and cancer:expression,methylation,polymorphisms and signaling (review)[J]. Int J Oncol, 2020, 56(4):867-878. doi:10.3892/ijo.2020.4979.
[16]	MIRZAEI S, GHOLAMI M H, HASHEMI F, et al. Advances in understanding the role of P-gp in doxorubicin resistance:molecular pathways,therapeutic strategies,and prospects[J]. Drug Discov Today, 2022, 27(2):436-455. doi:10.1016/j.drudis.2021.09.020.
[17]	SAU A, PELLIZZARI TREGNO F, VALENTINO F, et al. Glutathione transferases and development of new principles to overcome drug resistance[J]. Arch Biochem Biophys, 2010, 500(2):116-122. doi:10.1016/j.abb.2010.05.012.
[18]	SONG Y N, GUO X L, ZHENG B B, et al. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity[J]. Toxicol In Vitro, 2011, 25(4):937-943. doi:10.1016/j.tiv.2011.03.002.

木犀草素对白血病K562/ADR细胞多药耐药的逆转作用及机制研究

Study on the mechanism of luteolin reversing multidrug resistance in leukemia K562/ADR cells

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 5

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张兰英, 张福安, 刘茂茂, 陈杰, 周健, 刘钰婷, 欧阳瑶. CD1a⁺和CD83⁺树突状细胞在COPD小鼠肺组织中的分布及意义[J]. 天津医药, 2024, 52(9): 913-916.
[2]	杨敏, 潘艳莎, 张长玲, 陈红英, 郭渠莲, 刘文君. 儿童急性淋巴细胞白血病基线数据及早期治疗反应与预后的相关性[J]. 天津医药, 2024, 52(9): 954-958.
[3]	李冬生, 秦艺榕, 乔曼, 迟航, 崔青敏, 李晓秋. 清咳平喘颗粒对COPD急性加重期的临床疗效[J]. 天津医药, 2024, 52(8): 854-857.
[4]	马良, 胡立影, 石羽, 龙刚. 光学相干断层扫描血管成像技术在慢性肾脏病临床评估中的应用进展[J]. 天津医药, 2024, 52(8): 882-887.
[5]	吴静, 范志娟, 刘树业. 慢性乙型肝炎发展为肝细胞癌过程中血浆游离氨基酸水平的变化及临床意义[J]. 天津医药, 2024, 52(7): 738-742.
[6]	赵术彤, 丁运, 李月川, 赵晓赟, 耿华, 徐美林. 轻度慢性阻塞性肺疾病的病理特征及其与炎性因子的相关性[J]. 天津医药, 2024, 52(6): 643-647.
[7]	冯李婷, 李莉, 谢鑫, 王星. 天津地区部分居民慢性阻塞性肺疾病影响因素分析[J]. 天津医药, 2024, 52(4): 427-431.
[8]	宋喜, 葛益林, 李殷, 宋辉, 成嘉明. 慢性鼻窦炎患者MMP-9的表达及与上皮间质转化的相关性研究[J]. 天津医药, 2024, 52(3): 245-249.
[9]	纪晓娟, 韩浩, 张丽侠. 急性髓系白血病合并血流感染的病原菌分布与耐药性变迁及患者死亡的危险因素分析[J]. 天津医药, 2024, 52(2): 167-171.
[10]	付秀娟, 卢祖能. 糖尿病合并慢性炎性脱髓鞘性多发性神经根神经病研究进展[J]. 天津医药, 2024, 52(2): 220-224.
[11]	刘燕, 许靖, 马蕾, 曹冠亚, 赵凤德. AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系[J]. 天津医药, 2024, 52(12): 1261-1265.
[12]	周洁雯, 马丙南, 区静怡. 儿童鼠伤寒沙门菌肠炎细菌耐药性变迁及治疗分析[J]. 天津医药, 2024, 52(12): 1282-1285.
[13]	屠昌明, 田园, 汪鹏程, 任鹏, 赵寅生. SII、RAR与AECOPD患者病情严重程度及并发呼吸衰竭的关系[J]. 天津医药, 2024, 52(12): 1317-1321.
[14]	丁宁, 李亚杰, 刘敏琦, 李奇, 邢政, 褚晓蕾, 徐卫国. 慢性疼痛患者脑电时间-频率信号变化研究进展[J]. 天津医药, 2024, 52(12): 1340-1344.
[15]	于志鸿, 王小琴. 欧前胡素衍生物对COPD肺泡Ⅱ型细胞活性及耐药蛋白的影响[J]. 天津医药, 2024, 52(11): 1127-1130.